

Marco Matucci-Cerinic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6857024/publications.pdf>

Version: 2024-02-01

292
papers

15,575
citations

36299

51
h-index

21539

114
g-index

296
all docs

296
docs citations

296
times ranked

12550
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
3	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
4	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	7.4	566
5	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
6	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394
7	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 620-632.	0.9	351
8	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	10.7	348
9	Review: Evidence That Systemic Sclerosis Is a Vascular Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1953-1962.	6.7	339
10	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
11	Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 924-934.	0.9	184
12	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	6.5	170
13	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.9	168
14	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017, 38, 2649-2662.	2.2	163
15	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
16	Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 390-395.	0.9	146
17	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
18	Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 285-295.	3.4	133

#	ARTICLE	IF	CITATIONS
19	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 208-221.	8.0	115
20	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. <i>International Journal of Cardiology</i> , 2016, 217, 135-148.	1.7	114
21	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
22	Pathophysiology of Hemophilic Arthropathy. <i>Journal of Clinical Medicine</i> , 2017, 6, 63.	2.4	108
23	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
24	Lung CT Densitometry in Systemic Sclerosis. <i>Chest</i> , 2007, 131, 672-681.	0.8	97
25	Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. <i>Arthritis Research and Therapy</i> , 2017, 19, 206.	3.5	96
26	Raynaud's phenomenon and scleroderma dysregulated neuroendothelial control of vascular tone. <i>Arthritis and Rheumatism</i> , 1995, 38, 1-4.	6.7	95
27	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	7.4	95
28	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
29	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	3.8	91
30	Interstitial lung disease in systemic sclerosis: where do we stand?. <i>European Respiratory Review</i> , 2015, 24, 411-419.	7.1	90
31	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	3.4	84
32	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 1172-1177.	1.9	83
33	High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1140-1143.	0.9	82
34	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
35	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.9	79
36	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	3.4	77

#	ARTICLE	IF	CITATIONS
37	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.9	77
38	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	3.5	75
39	Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1700-1709.	0.9	72
40	Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1770-1776.	0.9	72
41	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
42	Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e37-e37.	0.9	71
43	Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 74-80.	1.2	70
44	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	1.9	67
45	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	4.8	67
46	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.7	62
47	Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2015, 14, 314-322.	5.8	60
48	Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. <i>Haematologica</i> , 2016, 101, 219-225.	3.5	60
49	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
50	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v67-v71.	1.9	59
51	Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjögren's syndrome: A systematic review from the Italian Society of Rheumatology. <i>Autoimmunity Reviews</i> , 2020, 19, 102447.	5.8	59
52	Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 72-76.	1.9	57
53	Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 268-275.	0.9	55
54	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53

#	ARTICLE	IF	CITATIONS
55	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	1.9	53
56	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
57	Mast cells in rheumatoid arthritis: friends or foes?. <i>Autoimmunity Reviews</i> , 2017, 16, 557-563.	5.8	52
58	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
59	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
60	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , 2020, 158, 1515-1525.	0.8	50
61	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	3.4	49
62	Oxidative stress in Systemic Sclerosis. <i>Molecular and Cellular Biochemistry</i> , 1999, 196, 85-91.	3.1	48
63	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 162-170.	5.6	48
64	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	3.4	45
65	Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1260-1268.	0.9	45
66	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	5.8	44
67	An expert opinion on PANDAS/PANS: highlights and controversies. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 91-98.	2.4	43
68	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.7	42
69	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 1680-1686.	2.0	42
70	Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 79-85.	3.4	42
71	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). <i>Rheumatology</i> , 2020, 59, 1938-1948.	1.9	42
72	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	3.9	42

#	ARTICLE	IF	CITATIONS
73	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	3.5	41
74	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	3.3	41
75	An optimal decision making model for supporting week hospital management. <i>Health Care Management Science</i> , 2011, 14, 74-88.	2.6	40
76	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.9	39
77	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.9	38
78	Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?. <i>Clinical Rheumatology</i> , 2016, 35, 1865-1872.	2.2	37
79	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	1.9	37
80	Unnecessary radiation exposure from medical imaging in the rheumatology patient. <i>Rheumatology</i> , 2011, 50, 1537-1539.	1.9	36
81	Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. <i>Rheumatology</i> , 2016, 55, 1826-1836.	1.9	36
82	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	1.9	35
83	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	8.0	35
84	Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1736-1740.	0.9	34
85	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
86	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33
87	Very early systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101428.	3.3	32
88	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 881-887.	2.0	32
89	Arthritis after SARS-CoV-2 infection. <i>Lancet Rheumatology</i> , The, 2021, 3, e324-e325.	3.9	32
90	Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183102.	2.5	32

#	ARTICLE	IF	CITATIONS
91	Determinants of Vitamin D Levels in Children, Adolescents, and Young Adults with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1884-1892.	2.0	31
92	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
93	Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 379-385.	0.9	31
94	Performance of ultra-high-frequency ultrasound in the evaluation of skin involvement in systemic sclerosis: a preliminary report. <i>Rheumatology</i> , 2020, 59, 1671-1678.	1.9	30
95	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 469-482.	3.0	29
96	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017, 122, S14-S17.	2.9	29
97	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. <i>European Journal of Internal Medicine</i> , 2020, 78, 17-25.	2.2	29
98	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	3.8	28
99	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
100	Edema-like marrow signal intensity: a narrative review with a pictorial essay. <i>Skeletal Radiology</i> , 2021, 50, 645-663.	2.0	28
101	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	4.1	28
102	Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions. <i>Current Rheumatology Reports</i> , 2017, 19, 65.	4.7	27
103	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
104	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	2.2	27
105	Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. <i>PLoS ONE</i> , 2016, 11, e0168706.	2.5	27
106	Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 221.	3.5	26
107	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial. <i>Respiratory Medicine</i> , 2016, 117, 254-263.	2.9	26
108	Proangiogenic effects of soluble Klotho on systemic sclerosis dermal microvascular endothelial cells. <i>Arthritis Research and Therapy</i> , 2017, 19, 27.	3.5	26

#	ARTICLE	IF	CITATIONS
109	Musculoskeletal hand involvement in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 329-334.	3.4	26
110	A Two-Step Immunomagnetic Microbead-Based Method for the Isolation of Human Primary Skin Teloocytes/CD34+ Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5877.	4.1	26
111	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	4.8	26
112	Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1190-1197.	2.0	25
113	Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1665-1674.	0.9	25
114	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	3.9	25
115	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
116	Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. <i>PLoS ONE</i> , 2015, 10, e0130166.	2.5	24
117	The "œmyth" of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?. <i>Arthritis Research and Therapy</i> , 2017, 19, 162.	3.5	24
118	Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. <i>Rheumatology International</i> , 2021, 41, 1743-1753.	3.0	24
119	Ilprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	3.6	23
120	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2020, 47, 249-254.	2.0	23
121	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. <i>Molecules</i> , 2021, 26, 5789.	3.8	23
122	Rheumatological diseases and cancer: the hidden variable of radiation exposure. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2065-2068.	0.9	22
123	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	3.0	22
124	Evaluation of autoimmune phenomena in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). <i>Autoimmunity Reviews</i> , 2014, 13, 1236-1240.	5.8	21
125	Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. <i>Rheumatology</i> , 2020, 59, 2024-2029.	1.9	21
126	Recent advances steer the future of systemic sclerosis toward precision medicine. <i>Clinical Rheumatology</i> , 2020, 39, 1-4.	2.2	21

#	ARTICLE	IF	CITATIONS
127	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	1.9	21
128	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096403.	2.7	21
129	Short-term effect of the combination of hyaluronic acid, chondroitin sulfate, and keratin matrix on early symptomatic knee osteoarthritis. <i>European Journal of Rheumatology</i> , 2015, 2, 106-108.	0.6	20
130	Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e192-e192.	0.9	20
131	Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 625.	2.5	20
132	The emerging role of lung ultrasound in COVID-19 pneumonia. <i>European Journal of Rheumatology</i> , 2020, 7, S129-S133.	0.6	20
133	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.8	20
134	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
135	Treatment of systemic sclerosis: is there any hope for the future?: Table A1. <i>RMD Open</i> , 2016, 2, e000260.	3.8	19
136	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	3.5	19
137	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19
138	Adipose-derived stem cells: Pathophysiologic implications <i>vs</i> therapeutic potential in systemic sclerosis. <i>World Journal of Stem Cells</i> , 2021, 13, 30-48.	2.8	19
139	Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 330-5.	0.8	19
140	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.7	18
141	The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. <i>Rheumatology</i> , 2012, 51, vii26-vii30.	1.9	17
142	Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. <i>Journal of Rheumatology</i> , 2016, 43, 592-598.	2.0	17
143	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , 2017, 84, 747-748.	1.6	17
144	¹⁸ F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.9	17

#	ARTICLE	IF	CITATIONS
145	Study of vitamin D status and vitamin D receptor polymorphisms in a cohort of Italian patients with juvenile idiopathic arthritis. <i>Scientific Reports</i> , 2020, 10, 17550.	3.3	17
146	Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1210-1217.	0.9	17
147	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 58-65.	1.7	17
148	Intact Calibers of Retinal Vessels in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 608-613.	2.0	16
149	The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?. <i>Arthritis Research and Therapy</i> , 2016, 18, 36.	3.5	16
150	Cross-Sectional Evaluation of Plasma Vitamin D Levels in a Large Cohort of Italian Patients with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 124-129.	1.3	16
151	N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor. <i>Frontiers in Immunology</i> , 2018, 9, 574.	4.8	16
152	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	2.0	16
153	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. <i>Arthritis Research and Therapy</i> , 2021, 23, 212.	3.5	16
154	Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 752-765.	0.8	16
155	Premedication prevents infusion reactions and improves retention rate during infliximab treatment. <i>Clinical Rheumatology</i> , 2016, 35, 2841-2845.	2.2	15
156	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
157	Interstitial pneumonia with autoimmune features: a new classification still on the move. <i>European Respiratory Review</i> , 2018, 27, 180047.	7.1	15
158	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. <i>Journal of Rheumatology</i> , 2021, 48, 82-86.	2.0	15
159	Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma. <i>Autoimmunity Reviews</i> , 2021, 20, 102899.	5.8	15
160	From Raynaud's Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach. <i>Current Rheumatology Reviews</i> , 2014, 9, 245-248.	0.8	15
161	Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 474-478.	0.9	14
162	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1032-1038.	0.9	14

#	ARTICLE	IF	CITATIONS
163	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	1.9	14
164	The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting. <i>Current Molecular Medicine</i> , 2022, 22, 209-239.	1.3	14
165	New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy. <i>Life</i> , 2021, 11, 610.	2.4	14
166	Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110596.	2.7	14
167	Osteoarthritis in the hands of Michelangelo Buonarroti. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 180-183.	2.0	13
168	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. <i>Rheumatology</i> , 2017, 56, 844-852.	1.9	13
169	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease – Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019, 46, 78-84.	2.0	13
170	The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091845.	2.7	13
171	Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1779-1785.	2.0	13
172	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	0.6	13
173	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v49-v52.	1.9	12
174	Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren's syndrome: a case report and literature review. <i>Clinical Rheumatology</i> , 2018, 37, 2001-2005.	2.2	12
175	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.9	12
176	Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 867-873.	3.4	12
177	Digital ulcer debridement in systemic sclerosis: a systematic literature review. <i>Clinical Rheumatology</i> , 2020, 39, 805-811.	2.2	12
178	Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. <i>Clinical Rheumatology</i> , 2021, 40, 1903-1912.	2.2	12
179	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA Dermatology</i> , 2021, 157, 851-858.	4.1	12
180	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12

#	ARTICLE	IF	CITATIONS
181	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.8	12
182	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	1.9	11
183	Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1256.	2.4	11
184	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	1.9	11
185	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.9	11
186	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021, 1, 253-263.	1.5	11
187	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , 2022, 61, S156-S164.	1.9	11
188	TNF- α /TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A. <i>Journal of Clinical Medicine</i> , 2019, 8, 939.	2.4	10
189	Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 3645-3656.	1.9	10
190	ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. <i>Rheumatology</i> , 2021, 60, 5509-5516.	1.9	10
191	Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1200-1204.	3.4	10
192	Impairment in the telocyte/CD34 ⁺ stromal cell network in human rheumatoid arthritis synovium. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2274-2278.	3.6	10
193	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.9	10
194	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	1.9	10
195	Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1362.	2.4	10
196	Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3717-3724.	4.3	9
197	The waterpolo shoulder paradigm: results of ultrasound surveillance at poolside. <i>BMJ Open Sport and Exercise Medicine</i> , 2017, 3, e000211.	2.9	9
198	Assessment of hand superficial oxygenation during ischemia/reperfusion in healthy subjects versus systemic sclerosis patients by 2D near infrared spectroscopic imaging. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 155, 101-108.	4.7	9

#	ARTICLE	IF	CITATIONS
199	Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6189.	4.1	9
200	Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 573-575.	0.9	9
201	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	2.7	9
202	Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13543.	3.4	9
203	Prediction and primary prevention of major vascular complications in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2021, 87, 51-58.	2.2	9
204	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	5.8	9
205	The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , 2022, 41, 573-579.	2.2	9
206	Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis. <i>Orthopedic Research and Reviews</i> , 2021, Volume 13, 255-273.	1.1	9
207	A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis. <i>Israel Medical Association Journal</i> , 2016, 18, 141-3.	0.1	9
208	The new frontier in systemic sclerosis: from epigenetics to new treatments. <i>Rheumatology</i> , 2015, 54, 1757-1758.	1.9	8
209	Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 575-577.	0.9	8
210	Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 6-20.	1.7	8
211	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 1141-1147.	1.9	8
212	Bone Marrow Edema. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 189-200.	3.0	8
213	Scleroderma-like Impairment in the Network of Telocytes/CD34+ Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12407.	4.1	8
214	Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review. <i>Frontiers in Medicine</i> , 2021, 8, 807982.	2.6	8
215	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.8	8
216	Fetal programming and systemic sclerosis. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 839.e1-839.e8.	1.3	7

#	ARTICLE	IF	CITATIONS
217	Avascular bone necrosis: An underestimated complication of systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e3-e5.	3.4	7
218	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , 2019, 70, 43-49.	2.2	7
219	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.7	7
220	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 241-246.	2.0	7
221	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	2.2	7
222	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , 2021, 11, 2165.	2.6	7
223	Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S148-52.	0.8	7
224	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 68-75.	0.8	7
225	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
226	Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. <i>Rheumatology</i> , 2019, 59, 580-585.	1.9	6
227	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 96-102.	1.9	6
228	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 111-117.	1.7	6
229	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	2.0	6
230	Pulmonary magnetic resonance imaging in systemic sclerosis: a jump in the future to unravel inflammation in interstitial lung disease. <i>Clinical Rheumatology</i> , 2021, 40, 3461-3464.	2.2	6
231	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	2.7	6
232	In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e149-e149.	0.9	6
233	Circulating Autoantibodies to Endothelial Progenitor Cells: Binding Characteristics and Association with Risk Factors for Atherosclerosis. <i>PLoS ONE</i> , 2014, 9, e97836.	2.5	6
234	Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn's disease: two overlapping diseases?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 195-200.	0.8	6

#	ARTICLE	IF	CITATIONS
235	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
236	Two-Dimensional near Infrared Spectroscopic Imaging of the Hand to Assess Microvascular Abnormalities in Systemic Sclerosis: A Pilot Study. <i>Journal of Near Infrared Spectroscopy</i> , 2015, 23, 59-66.	1.5	5
237	Is an intervention with a custom-made splint and an educational program useful on pain in patients with trapeziometacarpal joint osteoarthritis in a daily clinical setting?. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 773-780.	1.9	5
238	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	3.0	5
239	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1310.	2.4	5
240	The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	2.2	5
241	Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 179-183.	0.8	5
242	Predictive model of risk and severity of enteritis in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 1226-1236.	1.6	5
243	Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor- α Inhibitors Correlates with Increased Soluble Fas Levels. <i>Journal of Rheumatology</i> , 2014, 41, 1961-1965.	2.0	4
244	District disability, fatigue and mood disorders as determinants of health related quality of life in patients with systemic sclerosis. <i>Joint Bone Spine</i> , 2015, 82, 67-68.	1.6	4
245	Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. <i>Clinical Rheumatology</i> , 2019, 38, 1433-1436.	2.2	4
246	Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis. <i>Medicine (United States)</i> , 2019, 98, e16086.	1.0	4
247	Rehabilitation of the face and temporomandibular joint in systemic sclerosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110201.	2.7	4
248	Systemic Sclerosis. <i>European Medical Journal Rheumatology</i> , 0, , 100-109.	0.0	4
249	Inherited knee disorders in the Medici family. <i>Knee</i> , 2014, 21, 2-5.	1.6	3
250	Progress and Priorities in Systemic Sclerosis: The Next 10 Years " Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.7	3
251	Efficacy of Short-term Teriparatide for Hip Osteonecrosis. <i>Journal of Rheumatology</i> , 2016, 43, 2084-2085.	2.0	3
252	The Role of Imaging in COVID-19 Pneumonia Diagnosis and Management: Main Positions of the Experts, Key Imaging Features and Open Answers. <i>Journal of Cardiovascular Echography</i> , 2020, 30, S25-S30.	0.4	3

#	ARTICLE	IF	CITATIONS
253	Early diagnosis of systemic sclerosis, where do we stand today?. Expert Review of Clinical Immunology, 2022, 18, 1-3.	3.0	3
254	Autoimmune Tautology in a Complex Case of Polyautoimmunity: Systemic Sclerosis, Autoimmune Liver Involvement, Antiphospholipid Syndrome and Hashimoto's Thyroiditis. Israel Medical Association Journal, 2017, 19, 193-195.	0.1	3
255	The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 135-141.	0.8	3
256	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 68-75.	0.8	3
257	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.8	3
258	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. Turkish Journal of Medical Sciences, 2021, 51, 3391-3404.	0.9	3
259	Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 790-792.	2.0	2
260	Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort. Journal of Scleroderma and Related Disorders, 2021, 6, 165-169.	1.7	2
261	Response to: "Correspondence on "Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management" by Snarskaya and Vasileva. Annals of the Rheumatic Diseases, 2023, 82, e37-e37.	0.9	2
262	Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. Seminars in Arthritis and Rheumatism, 2021, 51, 425-429.	3.4	2
263	Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study. Lupus Science and Medicine, 2021, 8, e000521.	2.7	2
264	Information Survey on the Use of Complementary and Alternative Medicine. Medicina (Lithuania), 2022, 58, 125.	2.0	2
265	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clinical and Experimental Rheumatology, 2017, 35, 919-928.	0.8	2
266	Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?. Frontiers in Immunology, 2022, 13, 887279.	4.8	2
267	Introducing the Journal of Scleroderma and Related Disorders, a Challenge for the Future of Our Community. Journal of Scleroderma and Related Disorders, 2016, 1, 1-1.	1.7	1
268	A group of patients with Marfan's syndrome, who have finger and toe contractures, displays tendons alterations upon an ultrasound examination: are these features common among classical Marfan patients?. Internal and Emergency Medicine, 2016, 11, 703-711.	2.0	1
269	The Measurement of the Endothelial Glycocalyx as a New Biomarker of Endothelial Derangement in Systemic Sclerosis: A Challenge for the Future. Journal of Rheumatology, 2017, 44, 1572-1574.	2.0	1
270	Shoulder impingement syndrome in water polo players: muscle shortening manoeuvre controls pain intensity, recovers function and normalizes sonographic parameters. Journal of Ultrasound, 2022, 25, 667-673.	1.3	1

#	ARTICLE	IF	CITATIONS
271	Gait abnormalities in early rheumatoid arthritis with temporomandibular joint involvement. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 561.	0.8	1
272	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 43-48.	0.8	1
273	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.8	1
274	Treatment options in systemic sclerosis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 851-865.	0.8	0
275	A contribution to the debate about the possible different clinical severity between hemophilia A and B. <i>Haematologica</i> , 2016, 101, e430-e430.	3.5	0
276	AB0637â€¦IS VERY EARLY SYSTEMIC SCLEROSIS (SSC) A COMBINATION OF MILD AND EARLY DISEASE?. , 2019, , .		0
277	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
278	FRI0302â€¦SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY. , 2019, , .		0
279	The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?. <i>Rheumatology</i> , 2020, 59, 1198-1199.	1.9	0
280	The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by SjÅgrenâ€™s syndrome patients. <i>Rheumatology and Immunology Research</i> , 2021, 2, 113-119.	0.8	0
281	Systemic Sclerosis: Clinical Manifestations. <i>Current Rheumatology Reviews</i> , 2010, 6, 295-304.	0.8	0
282	Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. <i>Rheumatology and Immunology Research</i> , 2020, 1, 39-45.	0.8	0
283	A special European Journal of Rheumatology issue on systemic sclerosis: What and why?. <i>European Journal of Rheumatology</i> , 2020, 7, S137-S138.	0.6	0
284	A special European Journal of Rheumatology issue on systemic sclerosis: What and why?. <i>European Journal of Rheumatology</i> , 2020, 7, 137-138.	0.6	0
285	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 0, , .	1.9	0
286	Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go. <i>Rheumatology</i> , 2022, , .	1.9	0
287	A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 133-140.	0.8	0
288	A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0

#	ARTICLE	IF	CITATIONS
289	A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0
290	Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. <i>Rheumatology and Immunology Research</i> , 2022, 3, 31-37.	0.8	0
291	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
292	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0